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ABSTRACT
Objective: To establish an international patient-
reported outcomes (PROMs) study among prostate
cancer survivors, up to 18 years postdiagnosis, in two
countries with different healthcare systems and ethical
frameworks.
Design: A cross-sectional, postal survey of prostate
cancer survivors sampled and recruited via two
population-based cancer registries. Healthcare
professionals (HCPs) evaluated patients for eligibility to
participate. Questionnaires contained validated
instruments to assess health-related quality of life and
psychological well-being, including QLQ-C30, QLQ-
PR25, EQ-5D-5L, 21-question Depression, Anxiety and
Stress Scale (DASS-21) and the Decisional Regret Scale.
Setting: Republic of Ireland (RoI) and Northern
Ireland (NI).
Primary outcome measures: Registration
completeness, predictors of eligibility and response,
data missingness, unweighted and weighted PROMs.
Results: Prostate cancer registration was 80% (95% CI
75% to 84%) and 91% (95% CI 89% to 93%) complete
2 years postdiagnosis in NI and RoI, respectively. Of
12 322 survivors sampled from registries, 53% (n=6559)
were classified as eligible following HCP screening. In the
multivariate analysis, significant predictors of eligibility
were: being ≤59 years of age at diagnosis (p<0.001),
short-term survivor (<5 years postdiagnosis; p<0.001)
and from RoI (p<0.001). 3348 completed the
questionnaire, yielding a 54% adjusted response rate.
13% of men or their families called the study freephone
with queries for assistance with questionnaire completion
or to talk about their experience. Significant predictors of
response in multivariate analysis were: being ≤59 years at
diagnosis (p<0.001) and from RoI (p=0.016). Mean
number of missing questions in validated instruments
ranged from 0.12 (SD 0.71; EQ-5D-5L) to 3.72 (SD 6.30;
QLQ-PR25). Weighted and unweighted mean EQ-5D-5L,
QLQ-C30 and QLQ-PR25 scores were similar, as were the
weighted and unweighted prevalences of depression,
anxiety and distress.
Conclusions: It was feasible to perform PROMs studies
across jurisdictions, using cancer registries as sampling
frames; we amassed one of the largest, international,
population-based data set of prostate cancer survivors.
We highlight improvements which could inform future
PROMs studies, including utilising general practitioners to
assess eligibility and providing a freephone service.
Strengths and limitations of this study
▪ Both cancer registries used in this study are
national, population-based and judged as high
quality, and regularly collect vital status
information.
▪ However, using cancer registries as the sampling
frame meant that baseline and normative HRQoL
and psychological well-being data were not
collected.
▪ Validated questionnaires were used to measure
health-related quality of life (HRQoL), utility, psy-
chological well-being, and decisional regret to
facilitate comparisons with other prostate cancer
survivor studies and other diseases, and inform
policy regarding survivor needs and services.
▪ Although questionnaires were developed with
patient and clinical input, shorter questionnaires
with fewer questions might increase the
response rate and/or reduce data missingness.
Data missingness should be addressed in ana-
lysis by using appropriate methods.
▪ The study design was cross-sectional, but a high
proportion indicated a willingness to participate
in follow-up research.
▪ While the response rate was 54%, those who
were deemed ineligible and non-responders may
have different patient-reported outcomes
(PROMs) than those who were eligible and
responded. Weighting PROMs to the survivor
population was undertaken to minimise the
impact of these differences.
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INTRODUCTION
Prostate cancer is the most commonly diagnosed malig-
nancy in men in developed countries.1 As in many coun-
tries, incidence rates in the Republic of Ireland (RoI)
and Northern Ireland (NI) have increased signiﬁcantly
in the past two decades.2 3 RoI was estimated to have
had the highest prostate cancer incidence in Europe in
2008, while NI had the seventh highest incidence.4 This
difference was due, in part, to a twofold higher rate of
prostate-speciﬁc antigen (PSA) testing and prostate biop-
sies in RoI compared with NI.5 This in turn was driven
partly by differences in health systems between jurisdic-
tions; RoI has a mixed public/private healthcare system
and NI has a predominantly public healthcare system.
Rising incidence, lower stage at detection and improv-
ing survival means that prostate cancer is the most preva-
lent male cancer. Additionally, the majority of men
diagnosed with prostate cancer live for ≥5 years.6 Indeed,
in the USA, approximately 43% of all male cancer survi-
vors have had prostate cancer.7 Consequently, over the
past decade, there has been a growing interest in cancer
survivorship research, that is, on the lived experiences
and outcomes, including health-related quality of life
(HRQoL), of those diagnosed with and treated for
cancer. HRQoL is a multifaceted construct encompassing
symptom burden, and physical and psychological func-
tioning,8 and is increasingly being used as an end point
in assessing treatment effectiveness. Despite this, there
remains a paucity of population-based information on
HRQoL, experiences, needs and other outcomes of
short-term and long-term prostate cancer survivors. Lack
of population-based information makes it difﬁcult to
determine the morbidity burden associated with prostate
cancer, and its impact on men and their families.
Furthermore, it complicates international comparisons of
disease burden and the impact of alternative screening,
diagnostic and management strategies. It also hinders
policy-making and development of effective support
services.
Patient-reported outcomes (PROMs), without clinical
interpretation, are the optimum HRQoL measures.
However, it can be difﬁcult to recruit cancer survivors to
PROMs studies.9 Cancer registries are increasingly being
recognised as resources for PROMs and for other cancer
survivorship studies, as sampling frames10–13 or as
sources of clinical information when linked to other
data sets.14 To date, relatively few national and even
fewer international population-based PROMs studies
have been conducted, and many do not include older
and/or very long-term survivors.15
Our objective was to perform an international
population-based PROMs study from among short-term
(<5 years), long-term (5–9.9 years) and very long-term
(≥10 years postdiagnosis) prostate cancer survivors,16
identiﬁed through cancer registries in two countries. We
report on our experience of designing and conducting
the study, and on HRQoL measures. We also describe
recommendations to inform future research.
METHODS
Health systems
The island of Ireland comprises two jurisdictions, NI
(part of the UK) and the RoI. RoI has a mixed public/
private healthcare system. Approximately 45% of the
population have private health insurance, 30% have
medical cards entitling them to free healthcare in the
public system, and the other public patients make copay-
ments for public health services. NI has a primarily
public healthcare system, free at the point of use and
funded through taxation, similar to the National Health
Service in other parts of the UK.
Establishing an international population-based PROMs
study among prostate cancer survivors involved a number
of steps; (1) securing ethical approval; (2) identifying
potentially eligible participants from cancer registries;
(3) assessing participant eligibility; (4) questionnaire
design; (5) identifying methods to maximise survey
response and (6) linkage of questionnaire and cancer
registry data.
Ethical approval
Research governance approval was obtained from each
of the ﬁve NI Trusts. The study was conducted in accord-
ance with the Declaration of Helsinki,17 and survivors
consented to participate by returning completed ques-
tionnaires and/or signed consent forms.
Identification of participants from national cancer
registries in RoI and NI
The island of Ireland has two population-based cancer
registries, one each in RoI (National Cancer Registry
Ireland (NCRI)) and NI (Northern Ireland Cancer
Registry (NICR)), which have registered all cancer
cases since 1994 and 1993, respectively. Survivors were
deﬁned as men registered with invasive prostate cancer
(International Classiﬁcation of Diseases (ICD)10 C61),
diagnosed between 1 January 1995 and 31 March 2010,
and alive in November 2011. These limits were estab-
lished to allow for maximum registration of men with
prostate cancer and to ensure that the men had com-
pleted primary treatment(s) before being approached.
In total, 22 823 survivors were identiﬁed (n=17 304
(RoI); 5519 (NI)). A country-stratiﬁed random sample
of 12 322 men (54% of total; n=7422 (RoI); n=4900
(NI)) was selected, with roughly equal numbers of <5
and ≥5 years postdiagnosis.
Assessment of survivor eligibility
The same methods of recruitment were used in both jur-
isdictions, with modest reﬁnements for local and/or
national circumstances. In RoI and NI, similar to most
European countries,15 cancer registries do not have a
mandate to contact patients with cancer directly without
obtaining explicit clinician consent or agreement. This
is also a requirement of ethical committees and research
governance within RoI and NI. Therefore, survivors were
screened for eligibility by healthcare providers (HCPs);
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general practitioners (GPs; n=1745) in RoI and urology
clinical nurses (n=5) in NI. HCPs received a covering
letter detailing the study and a form for each potentially
eligible patient, which they were invited to complete
and return. These were dispatched by post to GPs and
freepost-addressed envelopes were supplied. Non-
responding GPs received up to two written reminders at
two-weekly intervals, followed by a telephone follow-up.
In NI, patient forms were dispatched by email.
A follow-up email was sent after 2 weeks, followed by a
telephone call after a further 2 weeks, if required. HCPs
were asked to indicate whether or not each man was eli-
gible to participate according to the criteria: the men
were (1) alive, (2) aware of their prostate cancer diagno-
sis, (3) otherwise well enough to receive and complete a
questionnaire (in particular, did not have a cognitive
impairment), (4) able to understand English and
(5) usually resident in RoI or NI.
Survey instrument design and content
Survivors were invited to complete a postal survey at one
time point. A core questionnaire was developed from
literature review and consultation with prostate cancer
survivors and clinicians. To facilitate international com-
parisons, validated instruments were incorporated.
The core questionnaire included questions related to
health at diagnosis; urinary (increased frequency, pain
while urinating, blood in urine) or sexual symptoms
(impotence/erectile dysfunction); comorbidities (heart
or lung disease, stroke, diabetes, depression, high blood
pressure, diverticular disease, bowel problems (constipa-
tion or diarrhoea)); PSA testing (and reasons for this);
method of diagnosis (biopsy or transurethral resection
of the prostate); and family history of prostate cancer.
Men were asked to identify primary treatment(s)
received from a list (radical prostatectomy, external beam
radiotherapy, androgen deprivation therapy (ADT),
brachytherapy, chemotherapy, active surveillance/watch-
ful waiting) with start and completion dates, and hospital
(s) attended. They were also asked to identify any/all
adverse effects experienced from a list (incontinence,
impotence, loss of sexual desire, bowel problems (diar-
rhoea/constipation), gynaecomastia, hot ﬂashes/ﬂushes
or sweats, fatigue, depression, other) with duration
(number of months/ongoing at questionnaire comple-
tion) and any intervention(s) received to alleviate symp-
toms. Severity of adverse effects was explored using a
ﬁve-point Likert scale (very mild (1) to very severe (5))
and men rated adverse effects as (1) the same, (2) not as
bad or (3) worse than expected.
General and prostate cancer-speciﬁc HRQoL were mea-
sured using EORTC QLQ-C3018 and QLQ-PR2519 instru-
ments, respectively. The EuroQoL EQ-5D-5L was included
to measure utility.20 The 21-question Depression, Anxiety
and Stress Scale (DASS-21) was employed to evaluate psy-
chological well-being.21 Treatment decision-making and
decisional regret were measured using the Control
Preference Scale, modiﬁed for the study, and Decision
Regret Scale (DRS), respectively.22 23
Sociodemographic questions included age at diagno-
sis, marital and educational status, and men were asked
if they would participate in future studies. Questions
related to employment at diagnosis and questionnaire
completion, productivity, ﬁnancial stress and strain had
been experienced previously.24 25
Both questionnaires were 28 pages long; the RoI
version included 152 questions and the NI version con-
tained 142 questions. The additional questions in the RoI
questionnaire related to out-of-pockets costs incurred
during diagnosis, staging, treatment and follow-up not
included in the NI questionnaire. Order of the questions
was largely the same in both questionnaires.
Methods to maximise survey response
Dillman’s Tailored Design Method, and methods that
have previously demonstrated an increase in response
were used to maximise questionnaire response.26 27 Men
were also provided with freephone number(s), one in
each jurisdiction, with instructions (on questionnaires
and information leaﬂets) to call if they required help
completing the questionnaire. Additionally, it was
branded as the PiCTure (Prostate Cancer Treatment, your
experience) study.26 Men in RoI were randomised to
receive either conditional or unconditional modest
ﬁnancial incentives.28 No incentives were used in NI.
Linkage of questionnaire and cancer registry data
Questionnaire responses were linked with cancer registra-
tion data to obtain/conﬁrm date of birth, date of diagno-
sis, clinical stage (Tumour-Lymph Node-Metastasis (TNM)
classiﬁcation, V.5) and Gleason grade (GG). Additional
clinical stage and GG information for NI responders was
sought, as completeness for these variables in the NICR
was low for early years.
Analysis
Analyses were performed using STATA V.13.1 (StataCorp
LP, 2013).
Completeness of cancer registration
Completeness of prostate cancer registration in each regis-
try was estimated using the ﬂow method.29 Completeness
estimates were calculated for all ages combined and by age
group for 2007–2010 with follow-up for deaths until 31
December 2012.
Predictors of eligibility to participate and questionnaire
response
Survival phases were categorised as short-term (<5), long-
term (5–9.9) and very long-term survivors (≥10 years
postdiagnosis).16 Univariate logistic regression analysis
was used to investigate potential predictors of eligibility:
age at diagnosis (≤59, 60–69, ≥70 years), survival phase
(short-term, long-term, very long-term survivors) and
jurisdiction (RoI, NI). Area of residence was further
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investigated by subdividing jurisdiction into eight health
board (HB) regions (RoI) and ﬁve Trusts (NI). Variables
signiﬁcant at the 5% level were considered for inclusion
in multivariate models; two multivariate models were run,
one with area of residence speciﬁed by jurisdiction and
one with area of residence speciﬁed by HB/Trust. The
same approach was taken to investigate predictors of
response among survivors deemed eligible to receive
questionnaires.
Acceptability of questionnaire
The proportion and mean number of missing questions
for QLQ-C30, QLQ-PR25, EQ-5D-5L, DASS-21 and DRS
were calculated, as a potential measure of acceptability.
The number of men who did not answer any survey-
speciﬁc treatment and/or adverse effect questions was
also calculated. Missingness was investigated by jurisdic-
tion, age at diagnosis and survival period, using analysis
of variance tests.
Unweighted and weighted PROMs
Using QLQ-C30 and QLQ-PR25, Global Health Status
(GHS), function, general and disease-speciﬁc symptom
scores were linearly transformed to values between 0
(lowest) and 100 (highest).18 19 Mean (SD) utility scores
were calculated using a crosswalk algorithm to convert
the EQ-5D-5L to the three-level version.20 A weighted-
health score based on UK normative data was assigned
to each individual in the absence of normative data for
Ireland. Scores for depression, anxiety and (di)stress
were calculated from the DASS-21.21 Men were classiﬁed
as having depression, anxiety and/or distress if they
scored ≥10, ≥8 and ≥15, respectively.21
Using survey methods, weights were computed based
on time since diagnosis, age at diagnosis and jurisdic-
tion. These were applied to responses by survey respon-
dents to generate weighted PROMs.
RESULTS
Completeness of cancer registration
At 2 years postdiagnosis, estimated registry completeness
for prostate cancer was 80% (95% CI 75% to 84%) in
NI and 91% (95% CI 89% to 93%) in RoI. This
increased to 89% (95% CI 85% to 93%) and 94% (95%
CI 92% to 95%) in NI and RoI, respectively, at 3 years
postdiagnosis. Completeness of case ascertainment was
higher for younger (≤59 years) compared with older
(≥80 years) age groups.
Predictors of eligibility of prostate cancer survivors
Of the random sample of 12 322 prostate cancer survi-
vors, just over half (53%; n=6559; ﬁgure 1) were classi-
ﬁed as eligible, following the HCP screening. In
multivariate analysis, men were signiﬁcantly more likely
to be deemed eligible if they were ≤59 years of age at
diagnosis, short-term survivors and from RoI (table 1).
Within each jurisdiction, a signiﬁcant difference in the
proportion of eligible survivors was observed by area of
residence.
Reasons for ineligibility and barriers encountered to
eligibility screening are shown in ﬁgure 1. Brieﬂy, in RoI,
despite receiving responses from 86% (1546/1745) of
Figure 1 Flow diagram describing the recruitment of prostate cancer survivors (GP, general practitioner).
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GPs contacted, 11% (827/7422) of survivors were lost
due to GP non-response and 12% (897/7422) due to
lack of up-to-date GP details, or GP’s refusal to collabor-
ate. A further 6% of RoI survivors were classiﬁed as ineli-
gible (400/7422) due to additional exclusion criteria
imposed by GPs (eg, survivors were full-time carers or
recently bereaved).
In NI, 6% (286/4900) of the random sample had no
recent contact with hospitals; thus, eligibility could not
be checked. No reason was disclosed for ineligibility of
36% (1767/4900) of the NI sample.
Cognition impairments or other debilitating health pro-
blems accounted for 5% (594/12 322) of the survivor
sample being deemed ineligible (n=345 (RoI), n=248
(NI)), 3% (362/12 322) were considered unaware of their
prostate cancer diagnosis (n=121 (RoI), n=241 (NI)), and
4% (503/12 322) were recently deceased (n=341 (RoI);
n=162 (NI)). Overall, a lower proportion of survivors aged
≥70 years at diagnosis were deemed eligible in NI com-
pared with RoI (36% and 52%, respectively).
Predictors of response
Following questionnaire dispatch, 5% (n=297) of poten-
tially eligible survivors were discovered to be ineligible
(eg, out-of-date address, ill health, recent death). After
removing these from the denominator, the adjusted
overall response rate was 54% (n=3348/6263). In multi-
variate analysis, men from RoI and who were ≤59 years
of age at diagnosis were signiﬁcantly more likely to
respond than older men and those from NI (table 1).
No signiﬁcant difference in response was observed by
time since diagnosis; ≥50% of men in each survival
phase returned a questionnaire.
Acceptability of questionnaire
Missing data
On average, 3% of questions designed to capture treat-
ment(s) received and adverse effects experienced were
unanswered (table 2). Overall, the proportion and mean
number of missing questions varied across HRQoL and
DRS instruments; the lowest was observed for EQ-5D-5L
(0.22) and highest for QLQ-PR25 (2.94). In univariate
analysis, mean number of missing questions was signiﬁ-
cantly associated with age at diagnosis for all sections—
lowest for men ≤59 years and highest for those
≥70 years of age at diagnosis. Very long-term survivors
had a signiﬁcantly higher mean number of missing ques-
tions than long-term and short-term survivors for each
instrument. Mean number of missing data for all instru-
ments, except QLQ-PR25, was higher for RoI than NI
respondents. Higher levels of missing data were found
for later sections of the questionnaire.
Freephone use
Overall, 14% (n=906/6559) of all questionnaire recipi-
ents or their families called the freephone (n=632
(RoI); n=274 (NI)). The main reasons for calling were
to inform us of their intention not to participate or
provide reasons for non-participation (19%; 173/906);
administrative issues (eg, requesting a replacement ques-
tionnaire (16%; 149/906)); queries regarding question-
naire content (8%; 76/906); being unaware of their
prostate cancer diagnosis (6%; 50/906); or having data
protection questions (eg, how their details were
obtained; 2%; 19/906). Sixty men (7%; 60/906) wanted
to complete the questionnaire by telephone. Family
members constituted 19% (169/906) of calls; these calls
were primarily to inform us that the questionnaire
recipient was: too ill or distressed to participate, unaware
of their prostate cancer diagnosis, or recently deceased.
For 20% of callers (n=177/906), the main reason for
calling was to talk about their experiences, both good
and bad, of living with prostate cancer.
Willingness to participate in future research
Almost three-quarters of respondents (overall: n=2423
(72%), n=1688 (72%; RoI), n=735 (73%; NI)) indicated
that they would participate in future research.
Weighted and unweighted values for QoL, utility and
psychological well-being measurements of respondents;
generalisability to all prostate cancer survivors
Compared with all prostate cancer survivors in Ireland,
long-term survivors were under-represented and survivors
>60 years at diagnosis were over-represented among
responders (table 3A). The overall mean unweighted
utility score for participants was 0.82 (SD 0.22) and the
GHS was 71.53 (SD 22.70; table 3B). Weighted and
unweighted mean utility scores did not differ. Weighting
resulted in lower GHS, physical, role and cognitive func-
tioning mean scores, and lower general and disease-
speciﬁc symptom mean scores for all except appetite loss,
constipation and ADT symptoms. Weighting also reduced
the prevalence of depression, anxiety and distress.
DISCUSSION
We conﬁrmed previous observations that cancer registries
are appropriate sampling frames for PROMs studies15
and extend the existing evidence by demonstrating that
international collaboration is feasible. To our knowledge,
we have amassed the largest, population-based data set of
prostate cancer survivors across two jurisdictions, which
operate under different health systems, and have differ-
ent legal and data protection environments. Using
cancer registry data, we determined HRQoL, utility and
prevalence of depression, anxiety and depression that
have been weighted for all prostate cancer survivors in
Ireland. Observations from this study could be used to
optimise future PROMs research in cancer.
Identification of potential participants from cancer
registries
Our aim was to be inclusive of all demographic groups,
including older men, and we targeted those who were at
2 years or more postdiagnosis such that registration was
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as complete as possible, and thus reduced possible sam-
pling bias. Completeness of prostate cancer registration
at 2 years postdiagnosis was lower than anticipated and
varied between the registries, probably due to differ-
ences in registration processes, available data sources,
rates of PSA testing and prostate biopsy, age and health
of men at diagnosis and treatment patterns.3 5 Younger
men and those undergoing surgery are likely to be regis-
tered before those managed by active surveillance or
watchful waiting or ADT. As cancer registries are focused
on completeness rather than timeliness of registration,
such differences should be considered when designing
and interpreting interjurisdiction studies, particularly
studies aiming to recruit prostate cancer survivors at less
than 2 years postdiagnosis.
Assessment of survivor eligibility and ethical approval
Despite collaborative and helpful HCPs, the need to
screen men selected from registries for eligibility to par-
ticipate meant that almost half of the randomised sample
was deemed ineligible to participate after checks in the
registries for recent deaths. In particular, some were
excluded due to subjective reasons outside the speciﬁed
exclusion criteria. Since this can affect population-basis
Table 3 Weighted and unweighted sociodemographic characteristics (%) and; patient-reported outcomes (means and
percentages) for PiCTure study respondents
Unweighted % Weighted %*
Sociodemographic characteristics
Jurisdiction RoI 70% 77%
NI 30% 23%
Age at diagnosis (years) ≤59 24% 22%
60–69 49% 44%
≥70 24% 34%
Survivorship phase Short-term 48% 42%
Long-tem 32% 43%
Very long-term 20% 16%
Patient-reported outcomes
EQ-5D-5L Utility score 0.82 0.82
Mobility 1.6 1.6
Self-care 1.2 1.2
Usual activities 1.6 1.7
Pain/discomfort 1.6 1.6
Anxiety/depression 1.4 1.4
EORTC QLQ-C30 GHS 71.53 71.15
Functioning subscales Physical functioning 82.16 81.54
Role functioning 80.91 80.57
Emotional functioning 83.51 83.66
Cognitive functioning 82.27 82.24
Social functioning 82.16 82.48
Symptoms subscales Fatigue 23.96 23.92
Nausea and vomiting 4.19 4.06
Pain 15.39 15.20
Dyspnoea 16.87 16.82
Insomnia 23.57 23.29
Appetite loss 7.00 7.00
Constipation 13.16 13.37
Diarrhoea 9.69 9.57
Financial difficulties 11.48 11.13
EORTC QLQ-PR25 Urinary symptoms 19.76 19.47
Urinary bother 15.57 14.79
Bowel symptoms 7.29 7.10
Treatment symptoms 10.62 10.17
Sexual activity 67.80 68.61
Sexual functioning 48.40 48.08
DASS-21 Depression 16.5% 16.3%
Anxiety 16.4% 16.1%
Distress 10.6% 10.4%
Depression, anxiety and distress were defined as men scoring ≥10, ≥8 and ≥15, on the respective subscales.21
*Using survey methods, weights were computed based on time since diagnosis, age at diagnosis and jurisdiction.
DASS, 21-question Depression, Anxiety and Stress (Di)Stress Scale; GHS, Global Health Status; NI, Northern Ireland; PiCTure, Prostate
Cancer Treatment, your experience; RoI, Republic of Ireland.
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data and generalisability of outcomes, effective methods
are needed to optimise this process. Physician’s notiﬁca-
tion rather than obtaining of physician’s consent30 or
contacting patients directly9 have been shown to be
effective recruitment mechanisms which reduce these
limitations. However, the latter would require changing
cancer registry mandates, ethical and research govern-
ance processes despite research showing that most
patients do not want physicians deciding whether they
should be approached for study participation.31 Securing
such changes in these data protection environments is
likely to be challenging.
In RoI, a choice had to be made about assessing eligi-
bility through hospital consultants or GPs. Using GPs
offered several advantages, including (1) reducing the
number of ethical applications required (from 28 to 1,
with time and cost savings), and (2) limiting the number
of patients to be screened by individual HCPs (n=1–32
(GPs); up to ≥1000 (hospital-based HCPs). Within this
study, our experience was that GPs in RoI excluded fewer
patients and provided more explanations for exclusion
than hospital-based HCPs in NI, possibly due to lengthy
patient lists. However, we cannot discount the possibility
that risk adversity in deﬁning someone as eligible, on the
part of nurses versus GPs, also contributed to the lower
proportion of NI survivors being deemed eligible. A
one-off study-speciﬁc modest monetary incentive to HCPs
may improve participation and cooperation;32 performing
additional data-ﬁnding exercises or implementing routine
data-ﬁnding exercises to maintain up-to-date GP and
contact information for patients within cancer registries
could also help optimise eligibility processes. It is difﬁcult,
however, to identify methods to reduce the propensity of
HCPs to exclude patients for non-study-speciﬁc reasons,
other than to reiterate the eligibility criteria. Furthermore,
while changes have been implemented to improve the
effectiveness and uniformity of ethical applications in
RoI,33 further improvements in ethical applications and
research governance are still required.
Response rate and item completeness; acceptability of the
questionnaire to survivors
Our overall response rate was similar to other studies using
cancer registries as sampling frames.15 Participation
among very long-term survivors was comparable to that
from men diagnosed more recently and older men
responded, albeit at a slightly lower response rate, than the
younger men. This is a major strength of this study as
older prostate cancer survivors, despite constituting the
majority of survivors, are frequently omitted from PROMs
studies.15 34–37
The questionnaires used were long, which may have
impacted on overall response.27 Although the RoI ques-
tionnaire included more questions than the NI version,
the response rate was higher, which may be due to RoI
survivors being slightly younger and/or use of incen-
tives.28 However, questionnaires returned by RoI survivors
had more missing data. Moderate levels of missingness
are expected with PROMs instruments administered by
post, the most common method of data collection for
PROMs studies. People are also less likely to answer ques-
tions on sensitive topics and much of PROMs data col-
lected, especially for prostate cancer, can be considered
sensitive. The level of missingness from all survivors
increased towards the end of the questionnaires, but this
was more evident from the RoI responders, which may
have been due to the higher number of questions and/
or the nature of these extra questions, which comprised
detailed time, travel and out-of-pocket cost questions
relating to prostate cancer diagnosis and treatment.
Furthermore, the highest proportion of missing data
from all survivors was observed for QLQ-PR25, which may
relate to its structure and/or content.19 The EORTC
QLQ-PR25 comprises 20 core and 5 conditional ques-
tions, organised into ﬁve multi-item subscales assessing:
urinary, bowel and hormone treatment-related symptoms;
sexual activity and sexual functioning (conditional on
being sexually active); and a single conditional item asses-
sing urinary bother due to use of incontinence aids.19
Most questions apply to the last week, and a few (relating
to sexual functioning) to the previous 4 weeks. While the
DASS and EORTC QLQ-C30 instruments did not contain
conditional questions, their content could be considered
sensitive by some, which may have contributed to rela-
tively high proportions of missing data. Similarly, the
structure of the DSR scale may have been misconstrued,
with 89% answering one of the ﬁve questions, but only
58% answering all questions.
Therefore, strategies to increase response and reduce
missingness are required. Future PROMs studies might
consider using shorter questionnaires/including fewer
questions, using alternative HRQoL instruments,38 and/or
employing appropriate statistical methods to deal with
data missingness.39
Methodologically, use of the freephone was successful
in: facilitating response/participation (through provid-
ing clariﬁcations and/or the opportunity to complete
the questionnaire by telephone); eliciting reasons for
non-response (including being unaware of their prostate
cancer diagnosis); and identifying further gatekeeping
issues. The volume of calls was unexpected and some
men were looking for support and advice; however, few
calls concerned data protection or unacceptability of
questionnaires. Providing the freephone service put
registry staff on the front line directly in contact with
patients and had resource implication for the registries.
Future researchers need to balance the advantages of a
freephone with costs (including staff training and
support) of providing the service.
HRQoL and psychological health responders;
generalisability to all prostate cancer survivors
and international comparisons
Despite signiﬁcant differences between responders and
all prostate cancer survivors within cancer registries, it
was possible, from survey methodologies, to weight
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PROMs to make them more representative for all pros-
tate cancer survivors. Compared with international
studies, the overall HRQoL of prostate cancer survivors
in Ireland, measured by the EQ-5D-5L utility score, was
similar to that of short-term prostate cancer survivors in
the UK,9 and the GHS and functional scores were
higher than those of newly diagnosed, untreated men
with prostate cancer in the EORTC reference popula-
tion.40 The prevalence of depression and anxiety is
slightly lower than that reported in a recent
meta-analysis,41 while the prevalence of distress is similar
to that previously described.42 Direct comparison of
PROMs between studies is complicated by differences in
eligibility criteria, data collection methods and response
rates. To enhance comparability between studies over
time, consideration might be given to standardising
PROMs to internationally agreed external standards (as
is routinely done for comparing cancer incidence rates).
Strengths and limitations
Both registries used in this study are national,
population-based and judged to be of high quality by
their inclusion in the Cancer Incidence in V Continents
series of the International Agency for Research on
Cancer, the cancer wing of WHO. However, using
cancer registries as sampling frames meant we did not
have baseline (ie, prediagnosis) HRQoL data as, by def-
inition, registries do not record an individual’s details
until they have a cancer diagnosis. The study was cross-
sectional, collecting data at a single time point; however,
the high level of willingness to participate in future
research suggests that longitudinal data could be col-
lected. PROMs are potentially sensitive to inaccuracies in
recall,43 but are more valid measures of patient outcome
than the clinician’s judgement. Although we weighted
PROMs by several key characteristics to make them more
representative of all survivors, it is possible that eligible
and ineligible survivors, and responders and non-
responders may have differed in other ways which would
have impacted the outcome.
Unanswered questions and future research
We will exploit this data set to investigate factors asso-
ciated with HRQoL and psychological well-being
throughout survivorship, identify subgroups whose
HRQoL has been adversely affected by prostate cancer
and investigate morbidity burden weighted for all pros-
tate cancer survivors. Data will inform cost-effectiveness
models on PSA testing and mapping of PROMs data on
the ﬁve-level EQ-5D-5L is planned. Findings will assist
researchers and their clinical teams with treatment
decision-making and the policymakers in determining
the most efﬁcient use of resources.
CONCLUSION
We have successfully used cancer registries, across two
jurisdictions to amass a large data set of prostate cancer
survivors, including older survivors and identiﬁed areas
throughout the process which could be optimised in
future PROMs research in cancer.
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